Pricing and reimbursement of orphan drugs in Italy

被引：0
|
作者：
Lopatriello, S.
Schivazappa, C.
Negrini, C.
Berto, P.
机构：
[1] PBE Consulting, Verona, Italy
[2] PBE Consulting, Milan, Italy
来源：
VALUE IN HEALTH | 2006年 / 9卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)63221-4
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
下载
收藏
页码：A208 / A209
页数：2
相关论文
共 50 条
  • [41] ASSESSMENT OF THE ORPHAN DRUG PRICING AND REIMBURSEMENT LANDSCAPE IN THE ASIA PACIFIC REGION
    Mukku, S. R.
    Pang, F.
    VALUE IN HEALTH, 2010, 13 (07) : A537 - A537
  • [42] MULTIPLE INDICATION PRICING, REIMBURSEMENT AND FUNDING DYNAMICS: THE CASE OF ORPHAN INDICATIONS
    Wild, L.
    Forster, L.
    VALUE IN HEALTH, 2011, 14 (07) : A335 - A336
  • [43] Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs
    Kolasa, Katarzyna
    Zwolinski, Krzysztof M.
    Kalo, Zoltan
    Hermanowski, Tomasz
    ORPHANET JOURNAL OF RARE DISEASES, 2016, 11
  • [44] IS THERE NO OPTIMAL APPROACH FOR ORPHAN DRUGS TO PATIENT ACCESS? RARE DISEASE IS NOT RARE AND NEEDS TO DEVELOP THE NEW PRICING AND REIMBURSEMENT SOLUTION
    Kim, S.
    Cho, Y.
    Shim, S.
    Lee, J.
    Kim, W.
    Bae, K.
    VALUE IN HEALTH, 2011, 14 (07) : A354 - A355
  • [45] The national drug formulary listing process for orphan drugs in South Korea: narrative review focused on pricing and reimbursement pathways
    Bang, Joon Seok
    Lee, Jong Hyuk
    EXPERT OPINION ON ORPHAN DRUGS, 2021, 9 (04): : 105 - 112
  • [46] Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs
    Katarzyna Kolasa
    Krzysztof M. Zwolinski
    Zoltan Kalo
    Tomasz Hermanowski
    Orphanet Journal of Rare Diseases, 11
  • [47] REIMBURSEMENT OF ORPHAN DRUGS UNDER EARLY BENEFIT ASSESMENT IN GERMANY
    Ecker, T.
    Schneider, D.
    Bot, D.
    VALUE IN HEALTH, 2016, 19 (03) : A281 - A281
  • [48] Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
    Stawowczyk, Ewa
    Malinowski, Krzysztof Piotr
    Kawalec, Pawel
    Bobinski, Rafal
    Siwiec, Jacek
    Panteli, Dimitra
    Eckhardt, Helene
    Simoens, Steven
    Agusti, Antonia
    Dooms, Marc
    Pilc, Andrzej
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [49] ACCESSIBILITY OF ORPHAN DRUGS IN KOREA: REIMBURSEMENT AND SUPPLY REFUSAL EXAMPLE
    Yun, J.
    Bae, S.
    VALUE IN HEALTH, 2018, 21 : S44 - S44
  • [50] COMPARATIVE ANALYSIS OF THE REIMBURSEMENT LANDSCAPE OF ORPHAN DRUGS ON AN INTERNATIONAL LEVEL
    Nozha, S.
    VALUE IN HEALTH, 2015, 18 (07) : A677 - A677
12345